Catalyst Pharmaceuticals stock rallies and outperforms peers in weak market
Updated
Updated · MarketWatch · May 7
Catalyst Pharmaceuticals stock rallies and outperforms peers in weak market
8 articles · Updated · MarketWatch · May 7
Shares rose 2.11% to $31.17 on Thursday as the Nasdaq fell 0.13% and the Dow dropped 0.63%.
The stock finished 4.28% below its 52-week high of $32.56, reached on 27 April.
Catalyst beat Johnson & Johnson and Pfizer, while Abbott also gained, and trading volume surged to 13.6 million against a 50-day average of 1.5 million.
Was the acquisition timed to capitalize on Catalyst's major patent victory for its key drug?
Why did Catalyst accept a $4.1B buyout when some models suggest its true value is significantly higher?